News (142)

Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates AQ
Madrigal Pharmaceuticals : Rezdiffra Approval Presentation PU
Transcript : Madrigal Pharmaceuticals, Inc. - Special Call
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) AQ
Madrigal Pharmaceuticals, Inc. Announces Management Changes CI
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer AQ
Madrigal Pharmaceuticals, Inc. Appoints CFO Changes CI
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results AQ
Transcript : Acelyrin, Inc., Q2 2023 Earnings Call, Aug 14, 2023
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights AQ
Acelyrin, Inc. Announces Resignation of Mardi C. Dier as Chief Financial Officer Effective August 15, 2023 CI
Acelyrin, Inc. Announces Resignation of Mardi C. Dier as Chief Business Officer Effective August 15, 2023 CI
Prelude Therapeutics Incorporated : January 2023 Corporate Presentation PU
Prelude Therapeutics Incorporated : November 2022 Corporate Presentation PU
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K) AQ
Ultragenyx Announces Departure of Chief Financial Officer GL
Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice President CI
Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Chief Financial Officer CI
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2022
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K) AQ
Prelude Therapeutics Incorporated : Q3 2022 Corporate Presentation PU
Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q) PU
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2022
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
ULTRAGENYX ANNOUNCES SALE OF A PORTION OF FUTURE NORTH AMERICAN ROYALTIES ON CRYSVITA FOR $500 MILLION TO OMERS CAPITAL MARKETS AQ
Ultragenyx Pharmaceutical : Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets - Form 8-K PU
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets GL
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 10:00 AM
Ultragenyx to Present at Goldman Sachs Global Healthcare Conference GL
Ultragenyx to Present at Goldman Sachs Global Healthcare Conference GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2022 Earnings Call, May 05, 2022
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference GL
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference GL
Prelude Therapeutics Incorporated : April 2022 Corporate Presentation PU
Prelude Therapeutics Incorporated : Q1 2022 Corporate Presentation PU
Prelude Therapeutics Incorporated : February 2022 Corporate Presentation PU
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2021 Earnings Call, Feb 10, 2022
Transcript : Ultragenyx Pharmaceutical Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 03:45 PM
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2021 Earnings Call, Nov 02, 2021
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2021 Earnings Call, Aug 02, 2021
ADAMAS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K) AQ
Adamas Pharmaceuticals, Inc. Announces the Resignation of Mardi C. Dier from the Board of Directors CI
1234NextSee all

Companies (1)

BCI MINERALS LIMITED 450 M $
Logo BCI Minerals Limited

BCI Minerals Limited is an Australia-based mineral resources company, which is engaged in developing an industrial minerals business with salt and potash as its initial focus. The Company is focused on its 100% owned Mardie Salt and Potash Project, which ...


Insiders

Picture Mardi Dier
Mardi Dier

Ms. Mardi C. Dier is a Chief Financial Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc., an Independent Director at Oric Pharmaceuticals, Inc. and an Independent Director at Adamas Pharmaceuticals, Inc. She is on the Board of Directors at Prelude Therapeutics, Inc., Oric Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. Ms. Dier was previously employed as a CFO, Chief Business Officer & Executive VP by Portola Pharmaceuticals, Inc., a Vice President-Investor Relations by Chiron Corp., a Director-Investment Banking by Prudential Equity Group LLC, a Senior Accountant by KPMG LLP, a Senior Accountant by KPMG Peat Marwick LLP, and a Director-Investment Banking by Prudential Securities. She also served on the board at Jewish Vocational Service, Inc. and Futures Strategic Trust. She received her undergraduate degree from Stanford University and an MBA from UCLA Anderson School of Management.



Picture Gregory Dier
Gregory Dier

Gregory Dier worked as an Associate Research Analyst at Hartford Investment Management Co..
Mr. Dier attended Middlebury College, where he received an undergraduate degree in 2013.




Picture Louise Dier
Louise Dier

Louise Dier served as an Independent Non-Executive Director at TClarke Plc from 2019 to 2022.
Prior to that, she worked as a Managing Director at David Chipperfield Architects Ltd., General Manager-United Kingdom at DO & CO Catering-Consult & Beteiligungs GmbH, and Head-Human Resources at IMG Europe Ltd.
She graduated from the University of Cambridge.


Picture Martina Dier
Martina Dier

Martina Dier has a current job as the Director of Global Communications at TeamViewer SE.









Picture Dagmar Mardi
Dagmar Mardi

Dagmar Mardi has a current job as a Director at Bostads AB Mimer.






Picture Rachid Mardi
Rachid Mardi

Rachid Mardi currently works as the Head-Client Accounting at Maroc Leasing SA.


Picture Mardi Ball
Mardi Ball

Mardi Ball currently works as an Accounting Director at HMH Advertising & Public Relations.






Picture Niranjan Mardi
Niranjan Mardi

Niranjan Mardi has worked as Vice Chairman & Chief Executive Officer at Tamil Nadu Maritime Board since 2014 and is currently working as a Director at Tamil Nadu State Marketing Corp.
Ltd.






Picture Chris Dier
Chris Dier

Chris Dier worked as a Principal at Intel Corp.
and as a Chief Financial Officer at The Solaria Corp.
and OuterBay Technologies, Inc. He obtained an undergraduate degree and an MBA from Santa Clara University.


Picture Martina Dier
Martina Dier

Martina Dier worked as the Head of Communications at Asstel Lebensversicherung AG and later as the Head of Corporate Communications & Public Relations at Mister Spex Se.
She completed her undergraduate degree at EBS Universität für Wirtschaft und Recht gGmbH.










Picture Mac Mardi
Mac Mardi

Mac Mardi is currently the Chief Executive Officer at Fuerst Day Lawson Ltd.
and a Director at Fuerst Day Lawson (U.S.A.) Ltd., FDL Holdings Ltd., FDL Acquisition No.
1 Ltd., and FDL Acquisition No.
2 Ltd.
He previously held the position of Chief Executive Officer at Invensys Ltd.
and RTS Ltd.
He was also the Chairman of IPBlaze A.
Additionally, he served as a Director at Fuerst Day Lawson Holdings Ltd.
from 2006 to 2020 and as the Vice President-Global Operations at DuPont Nutrition Biosciences ApS.
He was also a Principal at BI Software Ltd.






Picture Mardi Cannon
Mardi Cannon

Mardi Cannon has a current job as a Trustee at The Museum of Contemporary Art Denver.


Picture Mardi Peaster
Mardi Peaster

Mardi Peaster worked at Jones Lang LaSalle, Inc. from 2004 to 2019.
Her former job title was Senior Specialty Leasing & Marketing Manager, which she held from 2014 to 2019.





Picture Mardi de Verges
Mardi de Verges

Mardi de Verges has worked as the Chief Financial & Administrative Officer at Keen Energy Services LLC since 2011.
Prior to this, she held positions at CITGO Petroleum Corp.
as a Principal from 1989 to 2000, at Level 3 Parent LLC as a Senior Vice President-Finance, at Williams Industrial Services Group, Inc. as the Chief Financial Officer, at WilTel Communications LLC as the Chief Financial Officer, and at Arthur Andersen LLP as a Principal.
Ms. de Verges obtained her undergraduate degree from Oklahoma State University.









Picture Mohamed Mardi bin Ismail
Mohamed Mardi bin Ismail

Mohamed Mardi bin Ismail is currently working as the Head of Risk Management, Integrity & Compliance at TDM Bhd.

No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW